Figure 4.
Whole-body SPECT/CT image (A) of 99mTc-RGD-Lys-(Arg11)CCMSH in a B16/F1 melanoma-bearing C57 mouse at 2 h post-injection; HPLC profile (B) of radioactive urine sample of a B16/F1 murine melanoma-bearing C57 mouse at 2 h post-injection of 99mTc-RGD-Lys-(Arg11)CCMSH. Black arrow indicates the retention time of the original compound of 99mTc-RGD-Lys-(Arg11)CCMSH prior to the tail vein injection.